Aortic valve stenosis (AVS) is the most common acquired heart valve disease in the western world. The morbidity and mortality associated with AVS is tremendous and the 2-year mortality rate is around 50%. A complex process of endothelial dysfunction, immune cell infiltration, myofibroblastic and osteoblastic differentiation and subsequently calcification leads to remodeling and thickening of the aortic valve cups. The changes results in valve obstruction. The underlying pathophysiology of calcification are still unclear and no pharmacotherapy has been established to prevent aortic valve calcification. This review summarizes the current knowledge of pathomechanisms involved in aortic valve calcification and points out novel treatment strategies.
Publication:
Philip Roger Goody, Mohammed Rabiul Hosen, Dominik Christmann, Sven Thomas Niepmann, Andreas Zietzer, Matti Adam, Florian Bönner, Sebastian Zimmer, Georg Nickenig, Felix Jansen: Aortic Valve Stenosis – From Basic Mechanisms to Novel Therapeutic Targets; Arteriosclerosis, Thrombosis, and Vascular Biology 2020;40:885–900; DOI: 10.1161/ATVBAHA.119.313067
© 2020 American Heart Association, Inc.